TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07652242: Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

Sponsor: Immunomic Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07652242 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07652242 Rescue Dossier →